170 related articles for article (PubMed ID: 37543066)
1. Novel therapeutic strategies in glioma targeting glutamatergic neurotransmission.
Kumaria A; Ashkan K
Brain Res; 2023 Nov; 1818():148515. PubMed ID: 37543066
[TBL] [Abstract][Full Text] [Related]
2. Altered glutamatergic and inflammatory pathways promote glioblastoma growth, invasion, and seizures: An overview.
Feyissa AM; Rosenfeld SS; Quiñones-Hinojosa A
J Neurol Sci; 2022 Dec; 443():120488. PubMed ID: 36368135
[TBL] [Abstract][Full Text] [Related]
3. Pathway analysis of glutamate-mediated, calcium-related signaling in glioma progression.
Pei Z; Lee KC; Khan A; Erisnor G; Wang HY
Biochem Pharmacol; 2020 Jun; 176():113814. PubMed ID: 31954716
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy.
Lange F; Hörnschemeyer J; Kirschstein T
Cells; 2021 May; 10(5):. PubMed ID: 34067762
[TBL] [Abstract][Full Text] [Related]
5. Observations on the anti-glioma potential of electrical fields: is there a role for surgical neuromodulation?
Kumaria A
Br J Neurosurg; 2022 Oct; 36(5):564-568. PubMed ID: 33583293
[TBL] [Abstract][Full Text] [Related]
6. Glutamate and the biology of gliomas.
de Groot J; Sontheimer H
Glia; 2011 Aug; 59(8):1181-9. PubMed ID: 21192095
[TBL] [Abstract][Full Text] [Related]
7. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M
Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975
[TBL] [Abstract][Full Text] [Related]
8. Extracellular glutamate and IDH1
Tiburcio PDB; Gillespie DL; Jensen RL; Huang LE
J Neurooncol; 2020 Feb; 146(3):427-437. PubMed ID: 32020473
[TBL] [Abstract][Full Text] [Related]
9. Peritumoural glutamate correlates with post-operative seizures in supratentorial gliomas.
Neal A; Yuen T; Bjorksten AR; Kwan P; O'Brien TJ; Morokoff A
J Neurooncol; 2016 Sep; 129(2):259-67. PubMed ID: 27311724
[TBL] [Abstract][Full Text] [Related]
10. Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas.
Savaskan NE; Seufert S; Hauke J; Tränkle C; Eyüpoglu IY; Hahnen E
Oncogene; 2011 Jan; 30(1):43-53. PubMed ID: 20802520
[TBL] [Abstract][Full Text] [Related]
11. [Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications].
Blecic S; Rynkowski M; De Witte O; Lefranc F
Bull Cancer; 2013 Sep; 100(9):829-35. PubMed ID: 23883552
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.
Yohay K; Tyler B; Weaver KD; Pardo AC; Gincel D; Blakeley J; Brem H; Rothstein JD
J Neurosurg; 2014 Apr; 120(4):854-63. PubMed ID: 24484234
[TBL] [Abstract][Full Text] [Related]
13. Tumour associated epilepsy and glutamate excitotoxicity in patients with gliomas.
Liubinas SV; O'Brien TJ; Moffat BM; Drummond KJ; Morokoff AP; Kaye AH
J Clin Neurosci; 2014 Jun; 21(6):899-908. PubMed ID: 24746886
[TBL] [Abstract][Full Text] [Related]
14. Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging.
Neal A; Moffat BA; Stein JM; Nanga RPR; Desmond P; Shinohara RT; Hariharan H; Glarin R; Drummond K; Morokoff A; Kwan P; Reddy R; O'Brien TJ; Davis KA
Neuroimage Clin; 2019; 22():101694. PubMed ID: 30822716
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
16. Riluzole attenuates the effects of chemoconvulsants acting on glutamatergic and GABAergic neurotransmission in the planarian Dugesia tigrina.
Ramakrishnan L; Dalhoff Z; Fettig SL; Eggerichs MR; Nelson BE; Shrestha B; Elshikh AH; Karki P
Eur J Pharmacol; 2013 Oct; 718(1-3):493-501. PubMed ID: 23872399
[TBL] [Abstract][Full Text] [Related]
17. The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells.
Ching J; Amiridis S; Stylli SS; Bjorksten AR; Kountouri N; Zheng T; Paradiso L; Luwor RB; Morokoff AP; O'Brien TJ; Kaye AH
Oncotarget; 2015 Aug; 6(25):21301-14. PubMed ID: 26046374
[TBL] [Abstract][Full Text] [Related]
18. Oncogene AEG-1 promotes glioma-induced neurodegeneration by increasing glutamate excitotoxicity.
Lee SG; Kim K; Kegelman TP; Dash R; Das SK; Choi JK; Emdad L; Howlett EL; Jeon HY; Su ZZ; Yoo BK; Sarkar D; Kim SH; Kang DC; Fisher PB
Cancer Res; 2011 Oct; 71(20):6514-23. PubMed ID: 21852380
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway.
Zhang C; Yuan XR; Li HY; Zhao ZJ; Liao YW; Wang XY; Su J; Sang SS; Liu Q
Cell Physiol Biochem; 2015; 35(2):419-32. PubMed ID: 25613036
[TBL] [Abstract][Full Text] [Related]
20. Glutamatergic synaptic input to glioma cells drives brain tumour progression.
Venkataramani V; Tanev DI; Strahle C; Studier-Fischer A; Fankhauser L; Kessler T; Körber C; Kardorff M; Ratliff M; Xie R; Horstmann H; Messer M; Paik SP; Knabbe J; Sahm F; Kurz FT; Acikgöz AA; Herrmannsdörfer F; Agarwal A; Bergles DE; Chalmers A; Miletic H; Turcan S; Mawrin C; Hänggi D; Liu HK; Wick W; Winkler F; Kuner T
Nature; 2019 Sep; 573(7775):532-538. PubMed ID: 31534219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
